VolitionRx Limited has announced the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. The company also reported the first agreement with a leading pharmaceutical company to utilize its Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b clinical study, marking the first in-human clinical use of these biomarkers. Additionally, VolitionRx highlighted the commercial sale of its High Throughput Synthetic Sepsis method, which measures Neutrophil Extracellular Traps (NETs) activation and inhibition in whole blood. Through its Nu.Q® Discover platform, VolitionRx is now serving close to 100 clients worldwide, including pharmaceutical and diagnostic companies, some of which have advanced to late-stage clinical trials using VolitionRx assays as pharmacodynamic biomarkers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN84570) on February 10, 2026, and is solely responsible for the information contained therein.